Overview of Tazemetostat
Tazemetostat is an oral EZH2 inhibitor indicated for the treatment of:
Relapsed or refractory follicular lymphoma (FL) in patients who are not candidates for autologous stem cell transplantation
Certain patients with epithelioid sarcoma
It inhibits tumor growth by suppressing the activity of the EZH2 enzyme and regulating gene expression.Tazemetostat must be used strictly under medical supervision, with monitoring for adverse reactions and drug‑drug interactions.
Indications
Relapsed or Refractory Follicular Lymphoma (FL)
For adult patients, particularly those with EZH2 mutation‑positive disease who have received at least two prior systemic therapies.
Epithelioid Sarcoma
For patients with locally advanced or metastatic disease that is not completely resectable.
Eligibility should be confirmed by genetic testing for relevant mutation status.
Dosage and Administration
Recommended Dosage
800 mg orally daily, in two divided doses (400 mg twice daily, morning and evening).
May be taken with or without food.
Dose Adjustment
For severe adverse reactions: treatment may be interrupted or reduced to 400 mg once daily.
For patients with hepatic impairment: dosage adjustment based on Child‑Pugh classification is required.
Administration Instructions
Swallow tablets whole; do not crush or chew.
If a dose is missed and the delay is less than 6 hours, the dose may be taken as soon as remembered.
If more than 6 hours have passed, skip the missed dose. Do not double the dose.
Adverse Reactions
Common Adverse Reactions (≥20%)
Hematologic: anemia, thrombocytopenia, neutropenia
Gastrointestinal: nausea, vomiting, constipation
General: fatigue, pyrexia (fever)
Serious Adverse Reactions
Secondary malignancies (e.g., myelodysplastic syndrome)
Embryo‑fetal toxicity (contraindicated in pregnancy)
Increased risk of severe infection or bleeding
Important Notice
The information provided is not exhaustive.For complete details on dosage and side effects, refer to the full prescribing information.Consult your treating physician before starting tazemetostat. Do not initiate, adjust, or discontinue treatment without medical advice.
